| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yee-Sin Leo | |
| Mark Chen | |||
| Emily Rowe | |||
| Pei Yi Ng | |||
| Thiaghu Chandra | |||
| P2860 | cites work | Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion | Q57107899 |
| The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis | Q58874874 | ||
| Counterpoint: Efficacy of extracorporeal membrane oxygenation in 2009 influenza A(H1N1): sufficient evidence? | Q85160145 | ||
| The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews | Q21090775 | ||
| Systematic review of influenza resistance to the neuraminidase inhibitors | Q21261835 | ||
| Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children | Q24203905 | ||
| Neuraminidase inhibitors for preventing and treating influenza in children | Q24243136 | ||
| Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza | Q28146066 | ||
| Widespread use of neuraminidase inhibitors in Japan | Q28245805 | ||
| Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level | Q28253220 | ||
| Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies | Q28260818 | ||
| Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? | Q28260848 | ||
| Critically Ill patients with 2009 influenza A(H1N1) in Mexico | Q28261205 | ||
| Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza | Q28473860 | ||
| Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09 | Q28480880 | ||
| Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial | Q28684866 | ||
| Antivirals for influenza in healthy adults: systematic review. | Q30352729 | ||
| Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study | Q30353217 | ||
| Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. | Q30362392 | ||
| H1N1 2009 influenza virus infection during pregnancy in the USA. | Q30379409 | ||
| Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. | Q30381573 | ||
| Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome | Q57016763 | ||
| Oseltamivir. | Q30382225 | ||
| Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. | Q30382312 | ||
| Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. | Q30383137 | ||
| A systematic review to inform institutional decisions about the use of extracorporeal membrane oxygenation during the H1N1 influenza pandemic | Q30388204 | ||
| Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States | Q30388312 | ||
| Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection | Q30388857 | ||
| Safety of oseltamivir in pregnancy: a review of preclinical and clinical data | Q30391483 | ||
| Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. | Q30393490 | ||
| Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection | Q30396672 | ||
| Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. | Q30398715 | ||
| Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States | Q30400342 | ||
| Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores | Q30401605 | ||
| Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease | Q30402302 | ||
| Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children | Q30404404 | ||
| The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks | Q30404518 | ||
| Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection | Q30405579 | ||
| Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus | Q30412188 | ||
| Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza | Q30413369 | ||
| Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis | Q30423670 | ||
| Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients | Q30424329 | ||
| Influenza antiviral resistance in the Asia-Pacific region during 2011 | Q30425223 | ||
| Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic | Q30426114 | ||
| Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. | Q30427729 | ||
| Adjunctive therapies and immunomodulatory agents in the management of severe influenza | Q30429289 | ||
| Newer influenza antivirals, biotherapeutics and combinations | Q30456363 | ||
| Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. | Q30471016 | ||
| Complications: tracking down the data on oseltamivir | Q33517578 | ||
| Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO | Q33752972 | ||
| Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection | Q33876428 | ||
| Clinical signs and symptoms predicting influenza infection | Q33926001 | ||
| Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection | Q34023496 | ||
| Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren | Q34103279 | ||
| Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials | Q34192909 | ||
| Favipiravir (T-705), a novel viral RNA polymerase inhibitor | Q34374652 | ||
| Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis | Q34379610 | ||
| Neuraminidase inhibitors for influenza | Q34455162 | ||
| Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study | Q34634314 | ||
| Antiviral therapy for influenza virus infections | Q34740464 | ||
| Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis | Q34854860 | ||
| Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial | Q35003693 | ||
| Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients | Q35005030 | ||
| Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study | Q35121720 | ||
| Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers | Q36172477 | ||
| Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza | Q36584645 | ||
| Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment | Q36969884 | ||
| Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial | Q37083473 | ||
| Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications | Q37716488 | ||
| A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups | Q37917181 | ||
| Detection and management of antiviral resistance for influenza viruses | Q38161553 | ||
| Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial | Q38500366 | ||
| Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance | Q39239754 | ||
| Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial | Q40152886 | ||
| The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season | Q40219202 | ||
| A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. | Q40234299 | ||
| Early administration of oral oseltamivir increases the benefits of influenza treatment | Q40568853 | ||
| Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group | Q40625504 | ||
| Influenza and the rates of hospitalization for respiratory disease among infants and young children | Q41716369 | ||
| Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers | Q42110576 | ||
| Prevention and control of influenza: no easy task | Q42259347 | ||
| Tamiflu and neuropsychiatric disturbance in adolescents | Q42745964 | ||
| Outcomes of adults hospitalised with severe influenza. | Q43044944 | ||
| Fatal respiratory events caused by zanamivir nebulization | Q43046397 | ||
| High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia | Q43061117 | ||
| Fatal respiratory events caused by zanamivir nebulization | Q43185904 | ||
| A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. | Q43608172 | ||
| Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection | Q44480945 | ||
| Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock. | Q44613353 | ||
| A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases | Q44754491 | ||
| Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). | Q44805348 | ||
| Resistant influenza A viruses in children treated with oseltamivir: descriptive study | Q45036693 | ||
| Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States | Q45118572 | ||
| Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q45152293 | ||
| Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. | Q45974600 | ||
| Oseltamivir resistance--disabling our influenza defenses | Q46863506 | ||
| Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. | Q48719424 | ||
| ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia | Q48910582 | ||
| Critically ill patients with 2009 influenza A(H1N1) infection in Canada. | Q50580869 | ||
| The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. | Q53803600 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 227-244 | |
| P577 | publication date | 2014-06-25 | |
| P1433 | published in | Current treatment options in infectious diseases | Q26842059 |
| P1476 | title | Seasonal Human Influenza: Treatment Options | |
| P478 | volume | 6 |
Search more.